Sean Laaman
Stock Analyst at Morgan Stanley
(4.33)
# 650
Out of 5,182 analysts
27
Total ratings
68.18%
Success rate
14.06%
Average return
Main Sectors:
Stocks Rated by Sean Laaman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GENB Generate Biomedicines | Initiates: Overweight | $20 | $12.80 | +56.25% | 1 | Mar 24, 2026 | |
| EIKN Eikon Therapeutics | Initiates: Overweight | $32 | $9.87 | +224.21% | 1 | Mar 2, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $96 → $98 | $77.87 | +25.85% | 2 | Feb 25, 2026 | |
| EXEL Exelixis | Maintains: Equal-Weight | $48 → $49 | $44.96 | +8.99% | 6 | Feb 2, 2026 | |
| AXSM Axsome Therapeutics | Downgrades: Equal-Weight | $196 → $204 | $178.33 | +14.39% | 4 | Jan 8, 2026 | |
| CERT Certara | Maintains: Equal-Weight | $16 → $12 | $5.79 | +107.25% | 2 | Dec 18, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Overweight | $20 | $8.95 | +123.46% | 1 | Dec 5, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Overweight | $34 | $26.31 | +29.23% | 1 | Nov 21, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $90 → $115 | $68.46 | +67.98% | 3 | Oct 30, 2025 | |
| RMD ResMed | Maintains: Overweight | $298 → $304 | $230.26 | +32.02% | 2 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $383 | $305.64 | +25.31% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $3 → $1.5 | $2.33 | -35.62% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $67 | $66.98 | +0.03% | 1 | Feb 14, 2025 |
Generate Biomedicines
Mar 24, 2026
Initiates: Overweight
Price Target: $20
Current: $12.80
Upside: +56.25%
Eikon Therapeutics
Mar 2, 2026
Initiates: Overweight
Price Target: $32
Current: $9.87
Upside: +224.21%
BridgeBio Pharma
Feb 25, 2026
Maintains: Overweight
Price Target: $96 → $98
Current: $77.87
Upside: +25.85%
Exelixis
Feb 2, 2026
Maintains: Equal-Weight
Price Target: $48 → $49
Current: $44.96
Upside: +8.99%
Axsome Therapeutics
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $196 → $204
Current: $178.33
Upside: +14.39%
Certara
Dec 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $12
Current: $5.79
Upside: +107.25%
BridgeBio Oncology Therapeutics
Dec 5, 2025
Initiates: Overweight
Price Target: $20
Current: $8.95
Upside: +123.46%
MapLight Therapeutics
Nov 21, 2025
Initiates: Overweight
Price Target: $34
Current: $26.31
Upside: +29.23%
Disc Medicine
Oct 30, 2025
Maintains: Overweight
Price Target: $90 → $115
Current: $68.46
Upside: +67.98%
ResMed
Oct 21, 2025
Maintains: Overweight
Price Target: $298 → $304
Current: $230.26
Upside: +32.02%
Oct 20, 2025
Maintains: Overweight
Price Target: $350 → $383
Current: $305.64
Upside: +25.31%
Mar 7, 2025
Assumes: Underweight
Price Target: $3 → $1.5
Current: $2.33
Upside: -35.62%
Feb 14, 2025
Assumes: Overweight
Price Target: $67
Current: $66.98
Upside: +0.03%